Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.43 USD | +3.14% | -3.56% | -28.10% |
Apr. 09 | UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating | MT |
Apr. 03 | Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing | MT |
Financials (USD)
Sales 2024 * | 65.76M | Sales 2025 * | 121M | Capitalization | 2.2B |
---|---|---|---|---|---|
Net income 2024 * | -411M | Net income 2025 * | -442M | EV / Sales 2024 * | 12 x |
Net cash position 2024 * | 1.41B | Net cash position 2025 * | 1.17B | EV / Sales 2025 * | 8.49 x |
P/E ratio 2024 * |
-5.9
x | P/E ratio 2025 * |
-5.85
x | Employees | 445 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.18% |
Latest transcript on Denali Therapeutics Inc.
1 day | +3.14% | ||
1 week | -3.56% | ||
Current month | -24.81% | ||
1 month | -25.71% | ||
3 months | -8.54% | ||
6 months | -15.22% | ||
Current year | -28.10% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Schuth
FOU | Founder | 50 | 13-10-13 |
Ryan Watts
FOU | Founder | 48 | 13-10-13 |
Joe Lewcock
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Vicki Sato
CHM | Chairman | 75 | 15-03-31 |
Jay Flatley
BRD | Director/Board Member | 71 | 15-03-31 |
David Schenkein
BRD | Director/Board Member | 66 | 15-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.31% | 0 M€ | 0.00% | - | |
0.31% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 15.43 | +3.14% | 1,122,313 |
24-04-25 | 14.96 | -3.86% | 1,140,532 |
24-04-24 | 15.56 | -3.41% | 944,425 |
24-04-23 | 16.11 | +0.75% | 1,080,081 |
24-04-22 | 15.99 | -0.06% | 3,056,993 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.10% | 2.2B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- DNLI Stock